January 23, 2020
In patients with newly diagnosed multiple myeloma (MM) who are ineligible for high-dose chemotherapy and transplantation, adding daratumumab to bortezomib, melphalan, and prednisone (VMP) halved the risk of disease progression or death, compared with VMP alone, according to updated results from the phase III ALCYONE trial. The findings, which were published in The Lancet, also point...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand